

# Evaluation and Treatment of the Asymptomatic AS patient


신미승

가천의대 심장내과

# Evaluation and Treatment of the Asymptomatic AS patient

- Exercise Testing
- Indication for Surgery
- Statin Therapy

# Aortic Stenosis



# AORTIC STENOSIS

## Classification of Severity

---

	<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
Jet velocity (m/s)	< 3.0	3.0-4.0	> 4.0
Mean grad (mmHg)	< 25	25-40	> 40
Valve area (cm <sup>2</sup> )	> 1.5	1.0-1.5	< 1.0
Valve area index (cm <sup>2</sup> /m <sup>2</sup> )			< 0.6

# Indications for Surgery


Severe AS

*CLASS I*

---

- Symptoms
- Need for CABG or Aortic Surgery
- LV Dysfunction (EF < 0.50)

# Considerations in the Asymptomatic Patient




# CASE STUDY

---

84 YEAR OLD MAN


- ASYMPTOMATIC
- ECHO: Vmax 4.2 m/s, AVA 0.8 cm<sup>2</sup>, EF 0.60



# EVENT-FREE SURVIVAL

## Predictors

- V max
- $\Delta V$  max
- NYHA Class



# EVENT-FREE SURVIVAL


**N = 126**

**V max > 5.0 m/s**

**1 SCD, 8 Total**

## Predictors

- Calcium
- $\Delta V$  max



# Asymptomatic Aortic Stenosis

## Exercise Testing

---

### Exercise test indicators of risk

- Abnormal BP response
- NSVT (?)
- ST depression  $> 2$  mm (?)
- $\Delta$  mean gradient (?)
- Symptoms.....

Otto CM, et al. Circulation 1997;95:2262

Das P, et al. JACC 2001;37 (suppl A):489A

Lancellotti P, et al. Circulation 2005;112:1377

# Indications for Surgery

## Severe, Asymptomatic AS

### Class IIB

---

- Abnormal response to exercise
- High likelihood of rapid progression
- Delay from symptom onset to surgery
- “Extremely” severe AS (AVA < 0.6 cm<sup>2</sup>, V max > 5.0 m/s) with low (< 1%) operative mortality risk

# Indications for Surgery

Moderate AS

Class IIA

---

*Need for*

- CABG
- Other Valve
- Aortic Surgery

# RISK of AVR

---


- *Operative Risk\**
  - AVR 3-4 %
  - AVR/CABG 5-6 %
- *Lifetime Prosthesis Risk*
  - 1 % / yr

---

\* STS 2006


# EXERCISE TESTING

## Asymptomatic AS



# EXERCISE TESTING

## Asymptomatic AS



# **Exercise testing in asymptomatic pts with AS**

- **To elicit symptoms**
- **To ascertain the need for aortic valve replacement**

# Exercise testing in asymptomatic pts with AS

- Exercise echocardiography facilitate interpretation of exercise elicited symptoms in asymptomatic pts with severe AS
- Abnormal LV response to exercise may predict a poor outcome

# Determinants of an abnormal response to exercise


- Larger increase in mean transaortic pressure gradient (PG)
- Limited contractile reserve: inadequate increase in EF at exercise
- Increased in PG: smaller exercise-induced changes in AV area & in EF & new or worsening MR during exercise

# Asymptomatic AS

## When to operate, when to follow?

- Risk stratification with selection of those pts who are likely to develop symptoms and require surgery within a short time period
- The most important predictors of outcome
  - The degree of valvular calcification
  - The hemodynamic progression rate
  - The development of symptoms during exercise testing
  - Plasma levels of cardiac neurohormones

# Management Strategy for pts with Severe AS




2006 ACC/AHA  
Guideline. J Am Coll  
Cardiol 2006;48:e1

# Indications for Surgery in Asymptomatic AS

	<b>Class</b>
Asymptomatic patients with severe AS and systolic LV dysfunction (LV EF < 50%) unless due to other cause	<b>IC</b>
Asymptomatic patients with severe AS and abnormal exercise test showing symptoms on exercise	<b>IC</b>
Asymptomatic patients with severe AS and moderate to severe valve calcification, and a rate of peak velocity progression $\geq 0.3$ m/sec. per year	<b>IIaC</b>
Asymptomatic patients with severe AS and abnormal exercise test showing fall in blood pressure below baseline	<b>IIaC</b>
Asymptomatic patients with severe AS and abnormal exercise test showing complex ventricular arrhythmias	<b>IIbC</b>
Asymptomatic patients with severe AS and excessive LV hypertrophy ( $\geq 15$ mm) unless this is due to hypertension	<b>IIbC</b>

# Evaluation of adults with moderate AS



# Asymptomatic AS Patients

- Even with severe AS, the risk of sudden death is low (<1%) in the asymptomatic patient.
- Risk of surgery: <1% in a 55 YO man with no other medical conditions
- Operative mortality:
  - 7% for an 85 YO woman with HTN and CAD
  - > 24% for an 80 YO man with CAD, prior cardiac surgery, and renal dysfunction

# Asymptomatic AS Patients

- The balance is shifted towards watchful waiting until symptoms supervene.
- Appropriate management
  - Patient education about symptoms
  - The importance of promptly seeking medical attention once symptoms are present
  - Periodic echocardiography
  - Cardiovascular risk factor reduction
- In pts with asymptomatic moderate-to-severe AS who are undergoing other cardiac surgery, valve replacement should be considered.




# AORTIC SCLEROSIS

Focal Thickening/Calcification with Velocity < 2.5 m/sec




<u>5 YR EVENT</u>	<u>NL (n=3919)</u>	<u>Ao Scler (n=1610)</u>	<u>AS (n=92)</u>	<u>P (trend)</u>
Death	14.9%	21.9%	41.3%	<0.001
CV death	6.1%	10.1%	19.6%	<0.001
MI	6.0%	8.6%	11.3%	<0.001

# Aortic Stenosis




Mohler ER et al. Arterioscler Thromb Vasc Biol 1997;17:547

# Endothelial cell activation in diseased aortic valves



# Lipids, Inflammation and Genetics in the Pathogenesis of Valve Calcification




# AORTIC STENOSIS


## Effect of Statins

**A.**


1. Control Diet



2. Cholesterol




3. Cholesterol +  
Atorvastatin




**B.**


1. Control Diet




2. Cholesterol



3. Cholesterol +  
Atorvastatin




# AORTIC STENOSIS Rate of Progression



# AORTIC STENOSIS


## Effects of Atorvastatin



Cowell SJ. et al. (SALTIRE) NEJM 2005;352:2389

# Effects of Rosuvastatin on Progression of Aortic Stenosis

## Annualized Change



Moura LM, et al. (RAAVE). J Am Coll Cardiol 2007;49:554

# Simvastatin and ezetimibe in AS (SEAS) Study

- Randomized, double-blind, placebo-controlled, multicenter study of a minimum **4 yrs'** duration
- Effect of lipid lowering with ezetimibe/simvastatin 10/40 mg/day in pts with asymptomatic AS with peak transvalvular jet velocity 2.5-4.0 m/s
- Primary efficacy variables: AV surgery & ischemic vascular events, including C-V mortality
- Effect on echo. evaluated progression of AS
- **1,873 patients** (68+/-10 years, 39% women, mean maximum velocity 3.1+/-0.5 m/s) from 173 sites
- The SEAS Study is the largest randomized trial to date in pts with AS

# AS Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial

- Double-blind, placebo-controlled study, f/u 3-5 yrs
- Pts with **mild to moderate AS** are randomized to receive 40 mg/d of rosuvastatin or placebo.
- To determine whether pts with AS randomized to rosuvastatin will experience less progression in AS severity (aortic transvalvular gradients & AVA).
- To determine the effect of rosuvastatin on the rate of cardiac death and AVR and to assess the time to outcome
- Younger (58.1 +/- 13.6 years), **less severe AS** (AS jet velocity 3.2 +/- 0.4 m/s), great proportion (48.9%) of pts with bicuspid AV

감사합니다.